天津医药 ›› 2016, Vol. 44 ›› Issue (5): 629-631.doi: 10.11958/20150434

• 应用研究 • 上一篇    下一篇

rhEGF 凝胶对面部激素依赖性皮炎皮肤功能改善的临床研究

张秀丽 1, 2, 张理涛 3△   

  1. 1天津医学高等专科学校 (邮编 300222); 2天津医科大学研究生院; 3天津市中医药研究院附属医院
  • 收稿日期:2015-12-28 修回日期:2016-02-27 出版日期:2016-05-15 发布日期:2016-05-18
  • 通讯作者: △通讯作者 E-mail:zhanglitao@medmail.com.cn E-mail:zhanglitao8122@163.com
  • 作者简介:张秀丽 (1979), 女, 副教授, 硕士在读, 主要从事皮肤与性病学方面的研究 △通讯作者 E-mail:zhanglitao@medmail

Clinical study on the efficiency of rhEGF gel to skin function of facial hormone-dependent dermatitis

ZHANG Xiuli1,2, ZHANG Litao3△   

  1. 1 Tianjin Medical College, Tianjin 300222, China; 2 Graduate School of Tianjin Medical University; 3 Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
  • Received:2015-12-28 Revised:2016-02-27 Published:2016-05-15 Online:2016-05-18
  • Contact: Corresponding Author E-mail:zhanglitao@medmail.com.cn E-mail:zhanglitao8122@163.com

摘要: 摘要: 目的 研究重组人表皮生长因子(rhEGF)凝胶联合他克莫司治疗面部激素依赖性皮炎的临床效果, 并观察其对皮肤功能的影响及复发情况。方法 将 48 例面部激素依赖性皮炎门诊患者随机分为治疗组 (rhEGF 凝胶联合他克莫司) 和对照组 (单用他克莫司), 每组 24 例。于治疗前、 治疗 4 周后门诊复诊时测定患者面部皮损处表皮含水量、 油脂及经皮水分丢失 (TEWL); 于治疗后第 1、 2、 4 周按照湿疹皮炎严重指数评分 (EASI) 法计算疗效指数, 治疗期间观察患者不良反应及复发情况等。结果 与治疗前相比, 治疗 4 周后治疗组和对照组皮损表皮含水量、 油脂均升高, TEWL 降低 (均 P<0.05), 治疗前、 后 2 组间差异均无统计学意义。治疗 1 周治疗组总显效率与对照组差异无统计学意义(45.8% vs. 20.8%, P>0.05), 治疗 2、 4 周时, 治疗组总显效率均高于对照组(79.2% vs. 50.0%, 91.2% vs. 62.5%, 均 P<0.05)。治疗组治疗过程中均未出现不良反应, 且其复发率明显低于对照组 (12.5% vs. 37.5%, χ2=4.03, P<0.05)。结论 rhEGF 凝胶对面部激素依赖性皮炎有较好的辅助治疗效果, 可显著改善皮肤功能, 且复发率低。

关键词: 重组人表皮生长因子凝胶, 皮肤功能, 面部激素依赖性皮炎, 他克莫司

Abstract: Abstract:Objective To study the clinical effects of recombinant human epidermal growth factor (rhEGF) gel combined with tacrolimus treatment on facial hormone-dependent dermatitis, and to investigate its influence in skin function and recurrence of dermatitis. Methods Forty-eight outpatients with facial hormone-dependent dermatitis were randomly divided into treatment group (n=24, treatment with tacrolimus combined rhEGF gel) and control group (n=24, treatment with tacrolimus). The moisture of skin, sebum content and transepidermal water loss (TEWL) were examined before treatment and 4 weeks after treatment in two groups. Eczema area and severity index (EASI) were calculated at 1 week, 2 weeks and 4 weeks after treatment. The adverse reactions and recurrence of dermatitis were observed during the treatment as well. Results Compared with pre-treatment, the moisture of skin and sebum content were increased (P<0.05) and the TEWL was decreased (P<0.05) after 4-week treatment. The differences were not statistically significant between two groups. The obvious effective rate of the treatment group (45.8%) was not significantly different from that of the control group (20.8%) after 1 week of treatment (P>0.05), but it is much higher in treatment group after two-week treatment (79.2% vs. 50.0%, P< 0.05) and after four- week treatment (91.2% vs. 62.5% , P<0.05). Furthermore, there was no adverse reaction in the treatment group, and the recurrence rate was much lower in treatment group (12.5%) than that of the control group (37.5%, 2χ =4.03, P<0.05). Conclusion Recombinant human epidermal growth factor gel has an auxiliary curative effect on facial hormone-dependent dermatitis and can significantly improve skin function, and the recurrence rate of dermatitis is low.

Key words: 重组人表皮生长因子凝胶, 皮肤功能, 面部激素依赖性皮炎, 他克莫司